Results 211 to 220 of about 238,513 (311)

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Autoantibodies targeting G protein-coupled receptors and clinical outcome after ischemic stroke (PROSCIS-B). [PDF]

open access: yesJ Neurol
Miesenberger AS   +13 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Antitumour Effects of β-Blockers: A Narrative Review of the Literature. [PDF]

open access: yesCurr Issues Mol Biol
Melissaridou D   +6 more
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

The c‐Src inhibitor eCF506 diminishes opioid tolerance and reduces β‐arrestin2 recruitment

open access: yesBritish Journal of Pharmacology, EarlyView.
Morphine activation of μ receptors causes tolerance through c‐Src activation and β‐arrestin2 recruitment. c‐Src inhibition or degradation reduces β‐arrestin2 recruitment, μ receptor endocytosis, while causing receptor upregulation, all likely contributing to reduced morphine tolerance.
Samuel Singleton   +6 more
wiley   +1 more source

A nuclear ERK-ATF5 axis coordinates mitochondrial metabolism and thermogenic gene expression in brown adipocytes. [PDF]

open access: yesJ Endocrinol
Jang HJ   +12 more
europepmc   +1 more source

Reassessing Perioperative Management Strategies for Phaeochromocytoma and Paraganglioma Resections

open access: yes
ANZ Journal of Surgery, EarlyView.
Jun Wei Chong   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy